GAP Peptides, LLC was incorporated in the summer of 2017 with the vision of transforming peptide manufacturing and positively impacting health and wellness around the world.
Our provisional patent application for the GAP protecting group and GAP Peptide Synthesis was filed in December 2015, with a PCT filed in December of 2016. Our US national stage application was initiated in December 2017 and International patent filings commenced in the summer of 2018.
GAP Peptides, LLC offers a proprietary, cost-saving technology for peptide manufacture. Using innovative methods, we develop and optimize synthesis routes for peptides used in the cosmetic, pharma, diagnostic, and other industries. We then transfer these to our clients.
Our current patent portfolio comprises 4 patent families including 14 patent applications, covering key countries, including the U.S., EPO, Canada, China, Israel, India, Japan, Korea, Hong Kong, and Mexico. Our portfolio consists of patents that we own or license exclusively as a result of our foundational relationship with Texas Tech University.
Our clients benefit from of GAP peptide synthesis applied in early-stage R&D settings in labs at universities and commercial research centers. Sublicense opportunities are available for large scale production. Application of the methodology in commercial production settings, we predict, will open new doors for companies seeking to revitalize domestic manufacturing.
GAP Peptides, LLC is a privately held company.